102 related articles for article (PubMed ID: 22964480)
1. Regulation of NKG2D-ligand cell surface expression by intracellular calcium after HDAC-inhibitor treatment.
Jensen H; Hagemann-Jensen M; Lauridsen F; Skov S
Mol Immunol; 2013 Mar; 53(3):255-64. PubMed ID: 22964480
[TBL] [Abstract][Full Text] [Related]
2. The NKG2D ligand ULBP2 is specifically regulated through an invariant chain-dependent endosomal pathway.
Uhlenbrock F; Hagemann-Jensen M; Kehlet S; Andresen L; Pastorekova S; Skov S
J Immunol; 2014 Aug; 193(4):1654-65. PubMed ID: 25024379
[TBL] [Abstract][Full Text] [Related]
3. 2-deoxy D-glucose prevents cell surface expression of NKG2D ligands through inhibition of N-linked glycosylation.
Andresen L; Skovbakke SL; Persson G; Hagemann-Jensen M; Hansen KA; Jensen H; Skov S
J Immunol; 2012 Feb; 188(4):1847-55. PubMed ID: 22227571
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
Wu X; Tao Y; Hou J; Meng X; Shi J
Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
[TBL] [Abstract][Full Text] [Related]
5. A conserved WW domain-like motif regulates invariant chain-dependent cell-surface transport of the NKG2D ligand ULBP2.
Uhlenbrock F; van Andel E; Andresen L; Skov S
Mol Immunol; 2015 Aug; 66(2):418-27. PubMed ID: 25983110
[TBL] [Abstract][Full Text] [Related]
6. Vesicular stomatitis virus infection promotes immune evasion by preventing NKG2D-ligand surface expression.
Jensen H; Andresen L; Nielsen J; Christensen JP; Skov S
PLoS One; 2011; 6(8):e23023. PubMed ID: 21857986
[TBL] [Abstract][Full Text] [Related]
7. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
8. Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of Jurkat T cells.
Andresen L; Jensen H; Pedersen MT; Hansen KA; Skov S
J Immunol; 2007 Dec; 179(12):8235-42. PubMed ID: 18056367
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
Heinemann A; Zhao F; Pechlivanis S; Eberle J; Steinle A; Diederichs S; Schadendorf D; Paschen A
Cancer Res; 2012 Jan; 72(2):460-71. PubMed ID: 22102694
[TBL] [Abstract][Full Text] [Related]
10. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
[TBL] [Abstract][Full Text] [Related]
11. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
12. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.
Skov S; Pedersen MT; Andresen L; Straten PT; Woetmann A; Odum N
Cancer Res; 2005 Dec; 65(23):11136-45. PubMed ID: 16322264
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
14. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Bhat J; Dubin S; Dananberg A; Quabius ES; Fritsch J; Dowds CM; Saxena A; Chitadze G; Lettau M; Kabelitz D
Front Immunol; 2019; 10():569. PubMed ID: 30972064
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of short-chain fatty acid propionate induces surface expression of NKG2D ligands on cancer cells.
Høgh RI; Møller SH; Jepsen SD; Mellergaard M; Lund A; Pejtersen M; Fitzner E; Andresen L; Skov S
FASEB J; 2020 Nov; 34(11):15531-15546. PubMed ID: 32996653
[TBL] [Abstract][Full Text] [Related]
17. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
18. The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D.
Hagemann-Jensen M; Uhlenbrock F; Kehlet S; Andresen L; Gabel-Jensen C; Ellgaard L; Gammelgaard B; Skov S
J Biol Chem; 2014 Nov; 289(45):31576-90. PubMed ID: 25258323
[TBL] [Abstract][Full Text] [Related]
19. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors.
Valés-Gómez M; Chisholm SE; Cassady-Cain RL; Roda-Navarro P; Reyburn HT
Cancer Res; 2008 Mar; 68(5):1546-54. PubMed ID: 18316620
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis.
Li K; Mandai M; Hamanishi J; Matsumura N; Suzuki A; Yagi H; Yamaguchi K; Baba T; Fujii S; Konishi I
Cancer Immunol Immunother; 2009 May; 58(5):641-52. PubMed ID: 18791713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
